Search the Newsroom
Filter By
News Type
Showing 1 - 10 of 38 results
Eating Behaviors Altered with EoE
CHOP study reveals patients with eosinophilic esophagitis alter their eating behaviors to increase both chewing time and meal consumption time.
CHOP Researchers Validate Pediatric “Allergic March” in Large National Study
In the largest study of its kind, CHOP researchers have validated a population-level pattern of pediatric allergy development known as the “allergic march.”
Promising Use for Antibody Treatment for EoE
Two recent studies show dupilumab improves eosinophilic esophagitis symptoms and pathology for adolescents and young adults.
New Study Shows AML Ages Immune Cells, Leading to Poor Treatment Response
A new study has found that acute myeloid leukemia (AML) ages and exhausts immune cells, impairing their ability to fight off cancer.
First Approved CAR T-Cell Therapy Shows Continued Benefits Five Years Later
New data on show CAR T-cell therapy leads to durable remission and long-term survival in children and young adults with relapsed or refractory B-ALL.
CHOP Researchers Develop Allogeneic CART for Relapsed or Refractory T-ALL Using Base Editing
CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.
CHOP Brings Together Experts to Discuss Precision Medicine in Pediatric Cancer Care
More than 250 experts gathered in Philadelphia and virtually to discuss the latest scientific advancements and breakthroughs in pediatric precision medicine oncology.
Getting Unstuck
Personalized therapeutic approaches for children with eosinophilic esophagitis are gaining ground at CHOP.
Mini Guts
Bench-to-bedside research supports GI innovation at CHOP.
CHOP-Led Study Finds Bortezomib Improves Survival in Children with Newly Diagnosed T-Cell Lymphoblastic Lymphoma
In a COG trial, CHOP researchers found adding bortezomib to chemotherapy significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL).